Davenport & Co
HZNP

Davenport & Co’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Davenport & Co’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-5,450
Closed -$303K – 766
2020
Q2 		$303K Buy
+5,450
New +$233K ﹤0.01% 552
2020
Q1 		– Sell
-5,850
Closed -$212K – 762
2019
Q4 		$212K Buy
+5,850
New +$179K ﹤0.01% 668

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Avoro Capital Advisors
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Paulson & Co
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return

Davenport & Co's HZNP Position: Q3 2020 in Review

Davenport & Co sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2020, closing a stake of 5,450 shares — an estimated $303K sold.

Davenport & Co first reported a position in HZNP in Q4 2019 and held it in 2 quarters. The position peaked at $303K in Q2 2020. 433 funds tracked by Wall St. Rank hold HZNP as of Q3 2020.

  • Davenport & Co reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2020 after selling out during the quarter.
  • Davenport & Co sold 5,450 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2020, an estimated $303K.
  • Davenport & Co first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2019 and held it in 2 quarters.
  • Davenport & Co's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $303K in Q2 2020.
  • 433 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2020.

Based on Davenport & Co's 13F filing for Q3 2020, filed 15 Oct 2020.